NEOGENOMICS INC (NEO) Fundamental Analysis & Valuation

NASDAQ:NEO • US64049M2098

Current stock price

8.235 USD
+0 (+0.06%)
Last:

This NEO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. NEO Profitability Analysis

1.1 Basic Checks

  • NEO had positive earnings in the past year.
  • In the past year NEO had a positive cash flow from operations.
  • In the past 5 years NEO always reported negative net income.
  • The reported operating cash flow has been mixed in the past 5 years: NEO reported negative operating cash flow in multiple years.
NEO Yearly Net Income VS EBIT VS OCF VS FCFNEO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50M -100M -150M

1.2 Ratios

  • The Return On Assets of NEO (-7.94%) is worse than 72.00% of its industry peers.
  • Looking at the Return On Equity, with a value of -12.91%, NEO is doing worse than 63.00% of the companies in the same industry.
Industry RankSector Rank
ROA -7.94%
ROE -12.91%
ROIC N/A
ROA(3y)-5.99%
ROA(5y)-5.34%
ROE(3y)-10.33%
ROE(5y)-9.24%
ROIC(3y)N/A
ROIC(5y)N/A
NEO Yearly ROA, ROE, ROICNEO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -5 -10 -15

1.3 Margins

  • With a decent Gross Margin value of 43.21%, NEO is doing good in the industry, outperforming 74.00% of the companies in the same industry.
  • NEO's Gross Margin has been stable in the last couple of years.
  • The Profit Margin and Operating Margin are not available for NEO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 43.21%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y5.44%
GM growth 5Y0.65%
NEO Yearly Profit, Operating, Gross MarginsNEO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. NEO Health Analysis

2.1 Basic Checks

  • NEO does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for NEO has been increased compared to 1 year ago.
  • Compared to 5 years ago, NEO has more shares outstanding
  • The debt/assets ratio for NEO has been reduced compared to a year ago.
NEO Yearly Shares OutstandingNEO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
NEO Yearly Total Debt VS Total AssetsNEO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

2.2 Solvency

  • Based on the Altman-Z score of 1.36, we must say that NEO is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of 1.36, NEO is doing worse than 64.00% of the companies in the same industry.
  • NEO has a Debt/Equity ratio of 0.41. This is a healthy value indicating a solid balance between debt and equity.
  • NEO has a better Debt to Equity ratio (0.41) than 65.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.41
Debt/FCF N/A
Altman-Z 1.36
ROIC/WACCN/A
WACC7.41%
NEO Yearly LT Debt VS Equity VS FCFNEO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M 600M 800M 1B

2.3 Liquidity

  • NEO has a Current Ratio of 4.26. This indicates that NEO is financially healthy and has no problem in meeting its short term obligations.
  • NEO has a better Current ratio (4.26) than 92.00% of its industry peers.
  • NEO has a Quick Ratio of 3.94. This indicates that NEO is financially healthy and has no problem in meeting its short term obligations.
  • NEO has a better Quick ratio (3.94) than 91.00% of its industry peers.
Industry RankSector Rank
Current Ratio 4.26
Quick Ratio 3.94
NEO Yearly Current Assets VS Current LiabilitesNEO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. NEO Growth Analysis

3.1 Past

  • NEO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 20.00%, which is quite impressive.
  • NEO shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -3.04% yearly.
  • NEO shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 10.11%.
  • NEO shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 10.35% yearly.
EPS 1Y (TTM)20%
EPS 3YN/A
EPS 5Y-3.04%
EPS Q2Q%50%
Revenue 1Y (TTM)10.11%
Revenue growth 3Y12.58%
Revenue growth 5Y10.35%
Sales Q2Q%10.56%

3.2 Future

  • Based on estimates for the next years, NEO will show a very strong growth in Earnings Per Share. The EPS will grow by 46.80% on average per year.
  • Based on estimates for the next years, NEO will show a quite strong growth in Revenue. The Revenue will grow by 8.82% on average per year.
EPS Next Y33.97%
EPS Next 2Y62.68%
EPS Next 3Y55.16%
EPS Next 5Y46.8%
Revenue Next Year9.85%
Revenue Next 2Y9.79%
Revenue Next 3Y9.56%
Revenue Next 5Y8.82%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
NEO Yearly Revenue VS EstimatesNEO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M 800M 1B
NEO Yearly EPS VS EstimatesNEO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.5 -0.5

More info and screens

Find the best growth stocksShow best growing peers

1

4. NEO Valuation Analysis

4.1 Price/Earnings Ratio

  • NEO is valuated quite expensively with a Price/Earnings ratio of 68.63.
  • The rest of the industry has a similar Price/Earnings ratio as NEO.
  • The average S&P500 Price/Earnings ratio is at 27.95. NEO is valued rather expensively when compared to this.
  • A Price/Forward Earnings ratio of 51.22 indicates a quite expensive valuation of NEO.
  • NEO's Price/Forward Earnings is on the same level as the industry average.
  • NEO is valuated rather expensively when we compare the Price/Forward Earnings ratio to 38.68, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 68.63
Fwd PE 51.22
NEO Price Earnings VS Forward Price EarningsNEO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NEO Per share dataNEO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates NEO does not grow enough to justify the current Price/Earnings ratio.
  • A more expensive valuation may be justified as NEO's earnings are expected to grow with 55.16% in the coming years.
PEG (NY)2.02
PEG (5Y)N/A
EPS Next 2Y62.68%
EPS Next 3Y55.16%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. NEO Dividend Analysis

5.1 Amount

  • NEO does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

NEO Fundamentals: All Metrics, Ratios and Statistics

NEOGENOMICS INC

NASDAQ:NEO (4/21/2026, 11:11:02 AM)

8.235

+0 (+0.06%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)02-17
Earnings (Next)04-28
Inst Owners107.63%
Inst Owner Change-0.01%
Ins Owners1.24%
Ins Owner Change3.05%
Market Cap1.07B
Revenue(TTM)727.33M
Net Income(TTM)-108.03M
Analysts72.22
Price Target14.22 (72.68%)
Short Float %5.95%
Short Ratio4.29
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)47.26%
Min EPS beat(2)40.97%
Max EPS beat(2)53.54%
EPS beat(4)4
Avg EPS beat(4)56.53%
Min EPS beat(4)31.6%
Max EPS beat(4)100%
EPS beat(8)8
Avg EPS beat(8)186.32%
EPS beat(12)12
Avg EPS beat(12)158.94%
EPS beat(16)16
Avg EPS beat(16)128.09%
Revenue beat(2)2
Avg Revenue beat(2)0.65%
Min Revenue beat(2)0.13%
Max Revenue beat(2)1.18%
Revenue beat(4)2
Avg Revenue beat(4)-0.78%
Min Revenue beat(4)-2.68%
Max Revenue beat(4)1.18%
Revenue beat(8)4
Avg Revenue beat(8)-0.18%
Revenue beat(12)8
Avg Revenue beat(12)1.59%
Revenue beat(16)11
Avg Revenue beat(16)1.85%
PT rev (1m)0.8%
PT rev (3m)5.02%
EPS NQ rev (1m)-16.46%
EPS NQ rev (3m)-37.36%
EPS NY rev (1m)-3.8%
EPS NY rev (3m)-1.8%
Revenue NQ rev (1m)0.02%
Revenue NQ rev (3m)-1.57%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.01%
Valuation
Industry RankSector Rank
PE 68.63
Fwd PE 51.22
P/S 1.47
P/FCF N/A
P/OCF 204.91
P/B 1.28
P/tB 41.72
EV/EBITDA N/A
EPS(TTM)0.12
EY1.46%
EPS(NY)0.16
Fwd EY1.95%
FCF(TTM)-0.17
FCFYN/A
OCF(TTM)0.04
OCFY0.49%
SpS5.59
BVpS6.43
TBVpS0.2
PEG (NY)2.02
PEG (5Y)N/A
Graham Number4.16606 (-49.41%)
Profitability
Industry RankSector Rank
ROA -7.94%
ROE -12.91%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 43.21%
FCFM N/A
ROA(3y)-5.99%
ROA(5y)-5.34%
ROE(3y)-10.33%
ROE(5y)-9.24%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y5.44%
GM growth 5Y0.65%
F-Score4
Asset Turnover0.53
Health
Industry RankSector Rank
Debt/Equity 0.41
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 39.82%
Cap/Sales 3.71%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.26
Quick Ratio 3.94
Altman-Z 1.36
F-Score4
WACC7.41%
ROIC/WACCN/A
Cap/Depr(3y)45.34%
Cap/Depr(5y)60.15%
Cap/Sales(3y)4.93%
Cap/Sales(5y)6.82%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20%
EPS 3YN/A
EPS 5Y-3.04%
EPS Q2Q%50%
EPS Next Y33.97%
EPS Next 2Y62.68%
EPS Next 3Y55.16%
EPS Next 5Y46.8%
Revenue 1Y (TTM)10.11%
Revenue growth 3Y12.58%
Revenue growth 5Y10.35%
Sales Q2Q%10.56%
Revenue Next Year9.85%
Revenue Next 2Y9.79%
Revenue Next 3Y9.56%
Revenue Next 5Y8.82%
EBIT growth 1Y-3.14%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year150.01%
EBIT Next 3Y42.58%
EBIT Next 5Y34.35%
FCF growth 1Y36.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-25.53%
OCF growth 3YN/A
OCF growth 5Y29.07%

NEOGENOMICS INC / NEO Fundamental Analysis FAQ

What is the fundamental rating for NEO stock?

ChartMill assigns a fundamental rating of 4 / 10 to NEO.


Can you provide the valuation status for NEOGENOMICS INC?

ChartMill assigns a valuation rating of 1 / 10 to NEOGENOMICS INC (NEO). This can be considered as Overvalued.


Can you provide the profitability details for NEOGENOMICS INC?

NEOGENOMICS INC (NEO) has a profitability rating of 2 / 10.


What is the valuation of NEOGENOMICS INC based on its PE and PB ratios?

The Price/Earnings (PE) ratio for NEOGENOMICS INC (NEO) is 68.63 and the Price/Book (PB) ratio is 1.28.


How financially healthy is NEOGENOMICS INC?

The financial health rating of NEOGENOMICS INC (NEO) is 5 / 10.